1. Home
  2. IDCC vs LQDA Comparison

IDCC vs LQDA Comparison

Compare IDCC & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo InterDigital Inc.

IDCC

InterDigital Inc.

SELL

Current Price

$325.80

Market Cap

6.6B

Sector

Miscellaneous

ML Signal

SELL

LQDA

Liquidia Corporation

SELL

Current Price

$33.84

Market Cap

5.5B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
IDCC
LQDA
Founded
1972
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Multi-Sector Companies
Biotechnology: Pharmaceutical Preparations
Sector
Miscellaneous
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.6B
5.5B
IPO Year
2007
2020

Fundamental Metrics

Financial Performance
Metric
IDCC
LQDA
Price
$325.80
$33.84
Analyst Decision
Strong Buy
Buy
Analyst Count
4
8
Target Price
★ $462.67
$51.50
AVG Volume (30 Days)
166.1K
★ 3.4M
Earning Date
10-29-2026
11-02-2026
Dividend Yield
★ 0.84%
N/A
EPS Growth
N/A
★ 51.81
EPS
★ 5.51
1.26
Revenue
★ $307,404,000.00
$158,320,000.00
Revenue This Year
N/A
$325.27
Revenue Next Year
N/A
$9.02
P/E Ratio
$60.41
★ $21.28
Revenue Growth
N/A
★ 1031.18
52 Week Low
$249.14
$21.97
52 Week High
$412.60
$93.61

Technical Indicators

Market Signals
Indicator
IDCC
LQDA
Relative Strength Index (RSI) 45.79 33.00
Support Level $317.76 $30.35
Resistance Level $351.31 $42.62
Average True Range (ATR) 9.64 3.35
MACD -0.76 -1.44
Stochastic Oscillator 17.94 21.55

Price Performance

Historical Comparison
IDCC
LQDA

About IDCC InterDigital Inc.

InterDigital Inc is a research and development company focused on wireless, Video, Artificial Intelligence, and related Technologies. It designs and develops technologies that enable connected, immersive experiences in a broad range of communications and entertainment products and services. The majority of revenue is generated from fixed-fee patent license agreements, with a smaller portion coming from variable royalty agreements. Geographically, it operates in the United States, China, South Korea, Japan, Taiwan, and Europe, with the majority is from China.

About LQDA Liquidia Corporation

Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.

Share on Social Networks: